Spots Global Cancer Trial Database for sunitinib
Every month we try and update this database with for sunitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer | NCT03170180 | Stomach Neoplas... | Sunitinib Gefitinib Imatinib | 20 Years - | Samsung Medical Center | |
| A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours | NCT01396408 | Advanced Rare T... | Sunitinib Temsirolimus | 16 Years - | Canadian Cancer Trials Group | |
| A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma | NCT02623127 | Thymic Carcinom... | Sunitinib | 20 Years - | Seoul National University Hospital | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | NCT03035630 | Clear-cell Rena... RCC Kidney Cancer Clear-cell Kidn... | Avelumab Sunitinib | 18 Years - | Hoosier Cancer Research Network | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma | NCT02689167 | Kidney Neoplasm... Metastatic Rena... | Sunitinib | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma | NCT02555748 | Metastatic Rena... | Pazopanib Sunitinib | 18 Years - | Institut Claudius Regaud | |
| Erlotinib and Sunitinib in NSCLC | NCT00581789 | Non Small Cell ... | erlotinib, suni... | 18 Years - | University of Wisconsin, Madison | |
| SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma | NCT00089648 | Carcinoma, Rena... | Sunitinib | 18 Years - | Pfizer | |
| Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma | NCT01219751 | Metastatic Rena... | Sunitinib | 18 Years - | Asan Medical Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer | NCT00620347 | Lung Cancer | sunitinib | 18 Years - | National Cancer Center, Korea | |
| An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer | NCT00748358 | Prostatic Neopl... Neoplasms, Horm... Tumor Markers, ... Survival Rate Disease-Free Su... | sunitinib | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| SUTENT® In The First Line Treatment Of Renal Cell Carcinoma | NCT00460798 | Renal Cell Carc... | Sutent: observa... | - | Pfizer | |
| Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy. | NCT03140176 | Metastatic Rena... | Sunitinib | 18 Years - | Pfizer | |
| FOLFIRI and Sunitinib in Metastatic Colorectal Cancer | NCT00806663 | Metastatic Colo... Liver Metastase... | sunitinib added... | 18 Years - 80 Years | Central European Society for Anticancer Drug Research | |
| Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma | NCT00794950 | Urinary Tract U... | Sunitinib | 18 Years - | University of Michigan | |
| A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) | NCT00434356 | Metastatic Brea... | bevacizumab sunitinib paclitaxel | 18 Years - | Genentech, Inc. | |
| Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland | NCT00980213 | Neoplasms Renal Cell Carc... | sunitinib | 18 Years - 85 Years | Tampere University Hospital | |
| Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma | NCT00556049 | Renal Cell Carc... Neoplasm Metast... | Gemcitabine Sunitinib | 18 Years - | Massachusetts General Hospital | |
| SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | NCT00577382 | Mucosal Lentigi... Acral Lentigino... | Sunitinib | 18 Years - | Dana-Farber Cancer Institute | |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors | NCT01700699 | Differentiated ... | - | University of Salerno | ||
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors | NCT01803503 | Solid Tumors Breast Cancer Non-small Cell ... Prostate Cancer Gastric Cancer | Docetaxel Sunitinib | 18 Years - 99 Years | National University Hospital, Singapore | |
| IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | NCT01265901 | Metastatic Rena... | Sunitinib GM-CSF Cyclophosphamid... IMA901 | 18 Years - | Immatics Biotechnologies GmbH | |
| Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer | NCT04394975 | Primary Disease... | Biological : To... sunitinib | 18 Years - 80 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer | NCT00712504 | Advanced Solid ... Non Small Cell ... | sunitinib docetaxel | 18 Years - | Pfizer | |
| Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma | NCT01498835 | Soft Tissue Sar... | Sunitinib | 18 Years - | Heidelberg University | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Losartan + Sunitinib in Treatment of Osteosarcoma | NCT03900793 | Osteosarcoma | Losartan Sunitinib | 10 Years - 40 Years | University of Colorado, Denver | |
| Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib | NCT03592199 | Clear Cell Rena... | Sunitinib | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | NCT00715442 | Renal Cell Carc... | Sunitinib Nephrectomy | - | M.D. Anderson Cancer Center | |
| Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors. | NCT02058901 | Solid Tumors | Sunitinib | 18 Years - | Amsterdam UMC, location VUmc | |
| AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib | NCT00853372 | Advanced Renal ... | Sunitinib Trebananib | 18 Years - | Amgen | |
| An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy | NCT00226811 | Stomach Neoplas... | Sunitinib | 18 Years - | Pfizer | |
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | NCT01381822 | Advanced Renal ... Gastrointestina... Pancreatic Neur... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments | NCT04175262 | Metastatic Rena... | sunitinib | 18 Years - | Pfizer | |
| Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing | NCT03109015 | Carcinoma, Rena... | Sunitinib Sunitinib | 18 Years - | Duke University | |
| Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib | NCT03592199 | Clear Cell Rena... | Sunitinib | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma | NCT01185366 | Kidney Cancer | Everolimus Sunitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib in Cancer Patients | NCT01098903 | Cancer | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | ||
| Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma | NCT01070186 | Renal Cell Carc... | Sunitinib Tumor biopsy Nephrectomy Biomarkers | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI | NCT01020630 | Adenocarcinoma | Sunitinib Placebo | 18 Years - | Johannes Gutenberg University Mainz | |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer | NCT04523272 | Advanced Renal ... | TQB2450 Anlotinib Sunitinib | 18 Years - 80 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. | NCT03066427 | Clear Cell Rena... | Sunitinib | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors | NCT00528619 | Neoplasms | Sunitinib, Peme... | 18 Years - | Pfizer | |
| Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment | NCT06032728 | Renal Cell Carc... | Sunitinib | 18 Years - 75 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma | NCT01502228 | Renal Cell Carc... | 150-Water 62Cu-ethylglyox... Positron Emissi... Sunitinib | 18 Years - | Indiana University | |
| A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | NCT02684006 | Renal Cell Canc... | Avelumab (MSB00... Axitinib (AG-01... Sunitinib | 18 Years - | Pfizer | |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | NCT03673501 | Gastrointestina... | Ripretinib Sunitinib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer | NCT00748358 | Prostatic Neopl... Neoplasms, Horm... Tumor Markers, ... Survival Rate Disease-Free Su... | sunitinib | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | NCT01472081 | Renal Cell Carc... Clear-cell Meta... | Nivolumab Pazopanib Sunitinib Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery | NCT01164228 | Kidney Cancer | Gemcitabine Sunitinib | 18 Years - | Eastern Cooperative Oncology Group | |
| Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib | NCT01246843 | Metastatic Rena... GIST | 18 Years - | Radboud University Medical Center | ||
| A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone | NCT00457392 | Carcinoma, Non-... | erlotinib sunitinib erlotinib placebo | 18 Years - | Pfizer | |
| Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | NCT01147822 | Carcinoma, Rena... | Pazopanib Sunitinib | 18 Years - | Novartis | |
| Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib | NCT01506336 | Gastro Intestin... | masitinib sunitinib | 18 Years - | AB Science | |
| Savolitinib vs. Sunitinib in MET-driven PRCC. | NCT03091192 | Carcinoma Carcinoma, Rena... Kidney Neoplasm... Urologic Neopla... Kidney Diseases Neoplasms by Si... Enzyme Inhibito... Protein Kinase ... | Savolitinib Sunitinib | 18 Years - 130 Years | AstraZeneca | |
| Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib | NCT02713763 | Pancreatic Neur... | Sunitinib | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | NCT00522249 | Carcinoma, Rena... | Pegylated Alfa ... sunitinib erlotinib | 18 Years - | The Methodist Hospital Research Institute | |
| Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor | NCT00543049 | Platinum Refrac... Primary Cancer ... Cancer of the F... | Sunitinib SUNITINIB | 18 Years - | AGO Study Group | |
| Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma | NCT00843037 | Paraganglioma Pheochromocytom... | Sunitinib | 18 Years - | University Health Network, Toronto | |
| Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer | NCT01784978 | Metastatic Rena... | Sunitinib Everolimus | 18 Years - | Associació per a la Recerca Oncologica, Spain | |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | NCT03673501 | Gastrointestina... | Ripretinib Sunitinib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib | NCT01514448 | Metastatic Rena... | Everolimus (RAD... | 18 Years - | Novartis | |
| Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | NCT01306045 | Carcinoma, Non-... Carcinoma, Smal... Carcinoma, Thym... | AZD6244 MK-2206 Lapatinib Erlotinib Sunitinib Molecular Profi... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Sunitinib and Capecitabine for First Line Colon Cancer | NCT00961571 | Metastatic Colo... | sunitinib and c... | 18 Years - | Georgetown University | |
| Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma | NCT01108445 | Advanced Non-cl... | Everolimus Sunitinib | 18 Years - | Duke University | |
| Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer | NCT00393939 | Breast Neoplasm... | Sunitinib malat... Taxotere | 18 Years - | Pfizer | |
| Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response | NCT00694096 | Renal Cell Canc... | Sunitinib | 18 Years - | University of Utah | |
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | NCT00491738 | Renal Cell Carc... | bevacizumab sunitinib placebo | 18 Years - | Genentech, Inc. | |
| OPALINE : A Study Of Morbidity And Mortality At 2 Years | NCT02264665 | Pancreatic Neur... | sunitinib everolimus chemotherapies ... | 18 Years - 99 Years | Pfizer | |
| Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma | NCT01481870 | Metastatic Rena... | Sorafenib-sunit... Sunitinib-soraf... | 20 Years - 80 Years | Yamagata University | |
| Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) | NCT06390826 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Radionuclide Im... Sunitinib | 18 Years - | National Cancer Institute (NCI) | |
| SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | NCT06208748 | Gastrointestina... GIST | Bezuclastinib i... | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer | NCT00695292 | Small Cell Lung... | irinotecan Carboplatin sunitinib | 18 Years - | SCRI Development Innovations, LLC | |
| Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma | NCT03519542 | Metastatic Rena... | Sunitinib | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma | NCT01498835 | Soft Tissue Sar... | Sunitinib | 18 Years - | Heidelberg University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
